Close

BIO Statement on Growing American Food Exports Act of 2018

The Biotechnology Innovation Organization (BIO) today released the following statement in response to the introduction of the bipartisan “Growing American Food Exports Act of 2018” (S. 3103) by Senator Todd Young (R-IN), Senator Joe Donnelly (D-IN), Senator Roy Blunt (R-MO), and Senator Claire McCaskill (D-MO):

BIO Food and Agriculture Section Comments to FDA on Guidance on Consultation Procedures: Foods Derived from New Plant Varieties

February 9, 2017 The Biotechnology Innovation Organization (BIO) is pleased to submit these comments in response to the U.S. Food and Drug Administration’s (FDA) request for public input on a notice published in the Federal Register1 regarding information collection burdens associated with its “Guidance on Consultation Procedures: Foods Derived from New Plant Varieties.”

BIO Food and Agriculture Section Comments to FDA on Review of Existing General Regulatory and Information Collection Requirements

February 5, 2017 The Food and Agriculture Section of the Biotechnology Innovation Organization (BIO) is pleased to submit these comments in response to the U.S. Food and Drug Administration’s (FDA) request for public input on a notice published in the Federal Register entitled “Review of Existing General Regulatory and Information Collection Requirements of the Food and Drug Administration,” as well as several related Center-specific notices.

BIO Comments to FDA on “Agricultural Biotechnology Education and Outreach Initiative; Public Meetings; Request for Comments” (FDA-2017-N-5991; November 17, 2017)

Re: FDA-2017-N-5991: “Agricultural Biotechnology Education and Outreach Initiative; Public Meetings; Request for Comments” To whom it may concern: The Biotechnology Innovation Organization (BIO) appreciates this opportunity to provide comments to the Food and Drug Administration (FDA) on its proposed Agricultural Biotechnology Education and Outreach Initiative (FDA-2017-N-5991). BIO is the world's largest biotechnology trade association, representing small and large companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of agricultural, healthcare, industrial and environmental biotechnology products. BIO represents its members in a number of matters related to the uses of biology-based technologies in agriculture, animal health and human health.

BIO Statement on USDA Withdrawal of 340 Biotech Rules

The U.S. Department of Agriculture’s (USDA) Animal and Plant Health Inspection Service (APHIS) today announced its intention to withdraw its proposed revisions to regulations (7 CFR part 340) governing agricultural biotechnology.  The Biotechnology Innovation Organization (BIO) issued the following statement in response:

BIO Comments to USDA’s Office of Budget and Program Analysis on Identifying Regulatory Reform Initiatives, September 15, 2017

United States Department of Agriculture Jamie L. Whitten Building, Room 101-A 1400 Independence Ave SW Washington DC 20250 Re: Identifying Regulatory Reform Initiatives Dear Ms. Adcock: The Biotechnology Innovation Organization (BIO) is pleased to submit these comments in response to the USDA’s request for information on “Identifying Regulatory Reform Initiatives,” published in the Federal Register on July 17, 2017.1 Thank you for the opportunity to provide input as the U.S. Department of Agriculture (USDA or the Agency) considers opportunities to improve customer service and remove unintended barriers to participation in its programs in ways that least interfere with its customers and allow USDA to accomplish its mission.

BIO comments to USD-AMS on the National Bioengineered Food Disclosure Law (RE: Questions Under Consideration)

August 25, 2017

...

Dr. Yuan Yao and Dr. Henry Havel (Phytoption) at the 2017 BIO International Convention

Rob Wright interviews Dr. Yuan Yao and Dr. Henry Havel (Phytoption) at the 2017 BIO International Convention Buzz Center.

Jack Bobo (Intrexon) at the 2017 BIO International Convention

Mike Huckman interviews Jack Bobo (Intrexon) at the 2017 BIO International Convention Buzz Center.

BIO comments to FDA Regarding the Regulation of Intentionally Altered Genomic DNA in Animals

BIO appreciates this opportunity to provide comments to the Food and Drug Administration (FDA) on its request for comments on the draft guidance for industry (GFI) #187, entitled Regulation of Intentionally Altered Genomic DNA in Animals2. This draft guidance would revise GFI #187 entitled “Regulation of Genetically Engineered Animals Containing Heritable Recombinant DNA Constructs” (current GFI #187)3.